Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Apatinib in HER2-negative Breast Cancer
NCT03982485Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in breast cancer, sponsored by Renji Hospital. Started Oct 2018; status: active, not recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03982485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982485.